Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;17(5):6425-6434.
doi: 10.3892/mmr.2018.8711. Epub 2018 Mar 9.

Identification of differentially expressed genes and biological pathways in bladder cancer

Affiliations

Identification of differentially expressed genes and biological pathways in bladder cancer

Fucai Tang et al. Mol Med Rep. 2018 May.

Abstract

The purpose of the present study was to identify key genes and investigate the related molecular mechanisms of bladder cancer (BC) progression. From the Gene Expression Omnibus database, the gene expression dataset GSE7476 was downloaded, which contained 43 BC samples and 12 normal bladder tissues. GSE7476 was analyzed to screen the differentially expressed genes (DEGs). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed for the DEGs using the DAVID database, and a protein‑protein interaction (PPI) network was then constructed using Cytoscape software. The results of the GO analysis showed that the upregulated DEGs were significantly enriched in cell division, nucleoplasm and protein binding, while the downregulated DEGs were significantly enriched in 'extracellular matrix organization', 'proteinaceous extracellular matrix' and 'heparin binding'. The results of the KEGG pathway analysis showed that the upregulated DEGs were significantly enriched in the 'cell cycle', whereas the downregulated DEGs were significantly enriched in 'complement and coagulation cascades'. JUN, cyclin‑dependent kinase 1, FOS, PCNA, TOP2A, CCND1 and CDH1 were found to be hub genes in the PPI network. Sub‑networks revealed that these gene were enriched in significant pathways, including the 'cell cycle' signaling pathway and 'PI3K‑Akt signaling pathway'. In summary, the present study identified DEGs and key target genes in the progression of BC, providing potential molecular targets and diagnostic biomarkers for the treatment of BC.

Keywords: bioinformatics analysis; bladder cancer; differentially expressed genes; enrichment analysis; protein-protein interaction.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Volcano plot of the DEGs. The abscissa represents logFC and the ordinate represents-log10 (P-value). The red and green dots indicate DEGs, while the black dots represent genes that are not differentially expressed between bladder cancer and healthy control tissues. Red, upregulation; green, downregulation. DEG, differentially expressed gene; FC, fold-change.
Figure 2.
Figure 2.
The top 15 enriched Gene Ontology terms of upregulated (A) and downregulated (B) differentially expressed genes. DEG, differentially expressed gene.
Figure 3.
Figure 3.
The top five enriched pathways of upregulated (A) and downregulated (B) differentially expressed genes. DEG, differentially expressed gene.
Figure 4.
Figure 4.
Top 3 modules from the PPI network. (A) The top 3 significant modules were selected. (B) Module 1 of DEGs from the PPI network; (C) module 2 of DEGs from the PPI network; and (D) module 3 of DEGs from the PPI network. PPI, protein-protein interaction; DEG, differentially expressed gene.

Similar articles

Cited by

References

    1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol. 2017;71:96–108. doi: 10.1016/j.eururo.2016.06.010. - DOI - PubMed
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Pinto IG. Systemic therapy in bladder cancer. Indian J Urol. 2017;33:118–126. doi: 10.4103/iju.IJU_294_16. - DOI - PMC - PubMed
    1. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234–241. doi: 10.1016/j.eururo.2012.07.033. - DOI - PubMed
    1. Choueiri TK, Raghavan D. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: Persisting uncertainties. Nat Clin Pract Oncol. 2008;5:444–454. doi: 10.1038/ncponc1159. - DOI - PubMed

Substances